Addex Therapeutics Ltd ADR(ADXN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 28 at 7:58 PM ET (Korea 9/29 08:58)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -8.17 | Insider Own | 0.03% | Shs Outstand | 1.0M | Perf Week | -20.4% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.0M | Perf Month | -27.01% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 0.03% | Perf Quarter | -53.17% |
| Income | -0.01B | P/S | 27.82 | EPS this Y | - | Inst Trans | -23.12% | Short Ratio | 0 | Perf Half Y | -58.06% |
| Sales | 0.00B | P/B | 0.68 | EPS next 5Y | - | ROA | -106.04% | Short Interest | 0.00M | Perf YTD | -63.6% |
| Book/sh | 4.11 | P/C | 2.93 | EPS past 3/5Y | 46.11% 31.85% | ROE | -151.63% | 52W High | -76.52% ($11.97) | Perf Year | -68.57% |
| Cash/sh | 0.96 | P/FCF | - | Sales past 3/5Y | -48.38% -44.27% | ROIC | -210.31% | 52W Low | -9.35% ($3.10) | Perf 3Y | -62.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 3.79% | Gross Margin | 110.5% | Volatility(W/M) | 14.54% 9.65% | Perf 5Y | -98.51% |
| Dividend TTM | - | EV/Sales | 19.62 | Sales Y/Y TTM | -45.73% | Oper. Margin | -3139.72% | ATR (14) | 0.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.97 | EPS Q/Q | 18.74% | Profit Margin | -8307.92% | RSI (14) | 29.87 | Recom | 4.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.97 | Sales Q/Q | -71.24% | SMA20 | -19.6% ($3.5) | Beta | 1.49 | Target Price | $22.87 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/9/28 | SMA50 | -39.8% ($4.67) | Rel Volume | 0.49 | Prev Close | $3.65 |
| Employees | 3 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -58.29% ($6.74) | Avg Volume(3M) | 0.19M | Price | $2.81 |
| IPO | 2020/1/29 | Option/Short | No/Yes | Trades | 382 | Volume | 90,657 | Change | -23.01% |
🧠 A Switzerland-based clinical-stage biotech developing small-molecule drugs targeting the **metabotropic glutamate receptor (mGluR)** family involved in brain signaling. Its lead pipeline candidate, dipraglurant, was originally aimed at Parkinson's disease-related side effects but has recently been repositioned toward recovery from stroke and traumatic brain injury, while its GABAB PAM program is being advanced through a partnership with Indivior. The company is a micro-cap listed on Nasdaq as an ADR.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded less than usual That is 49% of its average volume.
ADXN has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,782. Peers typically go for $1,227.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.5%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
It ranks #575 of 592 in the industry
Based on market cap of $3M.
SPRC#574 SciSparc Ltd $3M PER - ADXN#575 Addex Therapeutics Ltd ADR $3M PER - 
LABT#576 Lakewood-Amedex Biotherapeutics Inc $3M PER - 
CMND#577 Clearmind Medicine Inc $3M PER - 
SILO#578 SILO Pharma Inc $3M PER - 
FAQ
What kind of company is ADXN?
ADXN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADXN?
The market cap of ADXN is approximately $3M, ranking 5,803 within its sector.
What is the 52-week high and low for ADXN?
ADXN has recorded a 52-week high of $11.97 and a low of $3.10.
